New Study Reveals Association Between Anti-Retroviral Therapy and Reduced Risk of Alzheimer's Disease

Strategic Insights -

Research conducted by the University of Virginia has made a groundbreaking discovery in the field of Alzheimer's disease research. The study evaluated the association between exposure to nucleoside reverse transcriptase inhibitors (NRTIs), a class of anti-retroviral drugs, and the development of Alzheimer's disease in two large health insurance databases in the United States. The findings suggest that exposure to NRTIs is associated with a significantly lower incidence of Alzheimer's disease, whereas other anti-HIV therapies were not found to have a similar effect.

Key Takeaways:

  • The study evaluated the association between NRTI exposure and subsequent development of AD in two large health insurance databases in the United States.
  • The study found that exposure to NRTIs was associated with a significantly lower incidence of AD in two of the largest health insurance databases in the United States.
  • The reduction in risk was observed in two large, diverse health insurance databases after correcting for numerous comorbidities known to be associated with AD.
  • Exposure to non-NRTIs, protease inhibitors, and integrase strand transfer inhibitors (INSTIs) was not associated with reducing AD incidence.
  • The study provides a rationale for prospective clinical testing of inflammasome inhibitors such as NRTIs in AD.
  • The research concluded that "Our work provides a rationale for randomized clinical trials of inflammasome inhibitors in AD."
  • Funders for this research include National Institutes of Health (NIH) - USA, UVA Strategic Investment Fund, National Institutes of Health (NIH) - USA, National Institutes of Health (NIH) - USA, South Carolina Center for Rural and Primary Healthcare, US Department of Veterans Affairs, Columbia VA Health Care System, Columbia, South Carolina, National Institutes of Health (NIH) - USA.

Statistics:

  • The study was conducted for a 24-year period in the United States Veterans Health Administration.
  • The study was also conducted for a 14-year period in the MarketScan database.
  • The reduction in risk of developing AD was observed in two large, diverse health insurance databases.
  • The study evaluated the association between NRTI exposure and subsequent development of AD in two large health insurance databases in the United States.

Sources:

  • Association of Nucleoside Reverse Transcriptase Inhibitor Use With Reduced Risk of Alzheimer's Disease Risk. Alzheimer's & Dementia, 2025;21(5).
  • Jayakrishna Ambati, Joseph Magagnoli, Tammy H. Cummings, S. Scott Sutton, Meenakshi Ambati, Joseph Nguyen, Claire C. Thomas, Vidya L. Ambati, and Bradley D. Gelfand. (2025). Association of Nucleoside Reverse Transcriptase Inhibitor Use With Reduced Risk of Alzheimer's Disease Risk. Alzheimer's & Dementia, 2025;21(5).
  • NewsRx. Research Conducted at University of Virginia Has Provided New Information about Veterans Health (Association of Nucleoside Reverse Transcriptase Inhibitor Use With Reduced Risk of Alzheimer's Disease Risk). AIDS Weekly. July 7, 2025; p 77.